Antibodies, Bispecific
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion
Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection
Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
Merck Acquires Clinical-Stage CD3xCD19 Bispecific Antibody for $700M
Merck, CD3xCD19 bispecific antibody, Curon Biopharmaceutical, clinical-stage, pharmaceutical acquisition
FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy
FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO
FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma
EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment
AbbVie’s Epkinly Enters Follicular Lymphoma Market, Competing with Roche’s Lunsumio
Epkinly, Lunsumio, follicular lymphoma, bispecific antibodies, AbbVie, Roche, FDA approval, cancer treatment
Amgen’s Blincyto Wins FDA Approval for Expanded Leukemia Use
Blincyto, Amgen, FDA Approval, Leukemia Treatment, Minimal Residual Disease (MRD), Acute Lymphoblastic Leukemia (ALL), Bispecific Antibody
Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment
Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO